Hologic Global Footprint: Genius 3D Mammography, Genius AI, and IVD Market Access
An FDA regulatory and market access footprint dossier of Hologic, mapping Genius 3D Mammography PMA P080003, Genius AI clearances, and Panther diagnostics.
Executive Summary
What does Hologic's medical-device regulatory footprint look like, including the PMA/510(k) approval history of Genius 3D Mammography and Genius AI Detection, the applicable product codes, and US women's-health market access?
Hologic, Inc. (NASDAQ: HOLX) is the global leader in breast cancer screening and a major women's-health diagnostics company, with an FDA footprint built on two pillars. First, digital breast tomosynthesis (DBT) under PMA P080003 (product code OTE, Radiology): the Selenia Dimensions 3D System was the first FDA-approved DBT system, approved February 11, 2011, extended through supplements S001 (2013, C-View synthesized 2D), S006 (2018, 3Dimensions system) and S008 (2019, high-resolution tomosynthesis). Second, AI computer-aided detection under 510(k) (product code QDQ, 21 CFR 892.2090): Genius AI Detection (K201019, cleared November 18, 2020) and Genius AI Detection 2.0 (K221449, October 6, 2022; K230096, May 23, 2023; K243341). Hologic has installed more than 5,000 3D Mammography systems in the US, more than 16 million US women receive a Genius exam each year, the Genius exam detects 20-65% more invasive breast cancers, and it is the only mammogram FDA-approved as superior to standard 2D for women with dense breasts. The women's-health IVD portfolio is anchored by the Panther molecular platform and the Aptima assay family.
What FDA Product Codes and Regulations Govern Hologic's Breast Health Portfolio?
Analyzing Hologic's regulatory strategy requires understanding how the FDA distinguishes between radiological imaging hardware (Class III, requiring Premarket Approval) and computer-aided detection software (Class II, cleared via the 510(k) pathway).
1. Product Code OTE: Digital Breast Tomosynthesis (DBT) System
This product code applies to the hardware platforms that capture 3D breast mammography images.
- Regulation Number: 21 CFR 892.1715 (Full-field digital mammography system)
- Classification: Class III (Premarket Approval - PMA)
- Description: An X-ray system that projects multiple low-dose exposures at different angles around the breast to reconstruct a three-dimensional volume of the tissue, minimizing tissue overlap.
- Associated Devices: Selenia Dimensions 3D System, 3Dimensions Mammography System.
2. Product Code QDQ: Radiological Computer-Assisted Detection (CAD) Software for Mammography
This product code applies to the AI algorithms that analyze DBT images to highlight suspicious areas for radiologist review.
- Regulation Number: 21 CFR 892.2090 (Radiological computer assisted detection/diagnosis software)
- Classification: Class II (Special Controls)
- Description: Software that processes digital mammography or tomosynthesis images using machine-learning algorithms to detect microcalcifications or soft tissue densities, presenting them with visual markers.
- Associated Software: Genius AI Detection, Genius AI Detection 2.0.
3. Product Code JAK & NME: Full-Field Digital Mammography (FFDM)
Historically, before DBT, Hologic's regulatory baseline was built on 2D digital mammography.
- Product Code JAK: Full-field digital mammography system.
- PMA Reference: P010025 (Hologic Selenia Full Field Digital Mammography System, approved in 2002). This served as the technological precursor to the 3D tomosynthesis platforms.
Comprehensive Hologic Breast Health Regulatory Footprint
| Product / Software | FDA Product Code | Regulation Number | FDA Classification | Primary Predicate / PMA Reference | Key Features / Indication |
|---|---|---|---|---|---|
| Selenia Dimensions 3D | OTE | 21 CFR 892.1715 | Class III (PMA) | P080003 | Baseline hardware for 3D digital breast tomosynthesis. |
| 3Dimensions System | OTE | 21 CFR 892.1715 | Class III (PMA) | P080003/S006 | Ergonomic stabilizing arm (SmartCurve); 3.7-second tomosynthesis scan. |
| Genius AI Detection | QDQ | 21 CFR 892.2090 | Class II (510k) | K201019 (predicate: iCAD PowerLook Tomo Detection V2, K182373) | Deep learning lesion detection and case workflow prioritization. |
| Genius AI Detection 2.0 | QDQ | 21 CFR 892.2090 | Class II (510k) | K221449 / K243341 | 12% specificity increase at matched sensitivity compared to v1. |
| Quantra Software | LLZ | 21 CFR 892.2050 | Class II (510k) | K163623 (Quantra 2.2) | Automated BI-RADS volumetric breast density assessment. |
| Affirm Contrast Biopsy | IZH | 21 CFR 892.1710 | Class II (510k) | K202294 | Stereotactic and tomosynthesis-guided contrast-enhanced biopsy workflow on the Affirm upright biopsy system. |
The Selenia Dimensions & 3Dimensions DBT Platform: PMA P080003 Genealogy
Hologic's dominance in the breast-imaging sector began on February 11, 2011, when the FDA approved PMA P080003 for the Selenia Dimensions 3D System. This was the first digital breast tomosynthesis (DBT) system approved for commercial sale in the United States, transitioning breast cancer screening from flat 2D projection imaging to multi-angle 3D reconstruction.
Selenia Dimensions 2D (P010025)
|
v (Transition to 3D Tomosynthesis hardware - Approved Feb 2011)
Selenia Dimensions 3D System (P080003)
|
v (C-View Synthesized 2D module added - Supplement S001, 2013)
Selenia Dimensions 3D + C-View
|
v (3Dimensions System hardware upgrade - Supplement S006, 2018)
3Dimensions System (P080003/S006)
|
v (High Resolution Tomosynthesis upgrade - Supplement S008, 2019)
3Dimensions System + High-Res Tomo
The Baseline Approval: P080003 (2011)
The original approval required extensive clinical trial data demonstrating that the combination of DBT (3D) and standard FFDM (2D) was superior to 2D mammography alone in detecting breast cancers, while reducing the rate of patient recalls for false-positive findings. The clinical study involved 10 independent radiologists who read images from 312 cancer cases and 300 non-cancer cases, confirming statistically significant improvements in both sensitivity and specificity.
Supplement S001: The C-View Synthesized 2D Image Module (2013)
Approved on May 16, 2013, P080003/S001 introduced C-View software.
- Clinical Need: Standard DBT required a patient to undergo both a 3D scan and a separate 2D scan, doubling the radiation dose.
- Solution: C-View utilized mathematical algorithms to construct a synthesized 2D image directly from the 3D tomosynthesis data slice set.
- Clinical Trial Support: The supplement was supported by clinical trial NCT00971087, which compared synthesized 2D images plus 3D tomosynthesis against traditional 2D plus 3D. The FDA's Summary of Safety and Effectiveness Data (SSED) confirmed that C-View maintained clinical performance while reducing radiation dose by approximately 45%, minimizing patient exposure.
Supplement S006: The 3Dimensions System (2018)
Approved on March 23, 2018, P080003/S006 cleared the commercial launch of the 3Dimensions Mammography System.
- Improvements: The 3Dimensions system introduced faster scan times (a 3.7-second tomosynthesis scan), a high-resolution display, and ergonomic enhancements designed to reduce patient discomfort during compression (the SmartCurve stabilizing system).
Supplement S008: High-Resolution Tomosynthesis (2019)
Approved on October 24, 2019, P080003/S008 cleared Hologic's high-resolution (Clarity HD) tomosynthesis software. This upgrade approximately doubled the in-plane tomosynthesis resolution on the 3Dimensions system, improving the visualization of fine microcalcifications and subtle architectural distortions.
Genius AI Detection: The 510(k) Clearance Genealogy of AI-CAD Software
As 3D mammography generated thousands of image slices per exam, radiologists faced a significant increase in reading time. To address this, Hologic developed deep-learning algorithms to act as a secondary reader, cleared under product code QDQ (Class II, 21 CFR 892.2090).
1. Genius AI Detection (510(k) K201019)
Cleared on November 18, 2020, K201019 was Hologic's first-generation deep-learning CAD software designed for digital breast tomosynthesis.
- Predicate Device: iCAD's PowerLook Tomo Detection V2 software (K182373, cleared December 6, 2018) — a Class II QDQ radiological CAD system that served as the legally marketed predicate for Hologic's first AI-CAD clearance on DBT.
- Algorithm Function: The software utilized convolutional neural networks (CNNs) to analyze DBT projection and reconstructed slices. It identified areas of interest, assigned a patient-level complexity score (to assist in workflow triage), and highlighted specific lesions with bounding boxes.
2. Genius AI Detection 2.0 (510(k) K221449)
Cleared on October 6, 2022, K221449 represented a major algorithmic upgrade.
- Key Modification: The 2.0 version utilized a deeper neural network architecture trained on a significantly larger dataset of biopsy-proven cancer cases.
- Performance Metrics: The clearance summary demonstrated a 12% increase in specificity at a matched sensitivity level compared to the first-generation K201019 software. This improvement directly translated to fewer false-positive flags, reducing radiologist fatigue.
3. Extended AI Clearances: K230096 and K243341
- K230096 (Cleared May 23, 2023): This clearance expanded Genius AI Detection 2.0 to be compatible with a broader range of Hologic acquisition platforms, including older Selenia Dimensions systems, and integrated new triage metrics to prioritize suspicious cases in the PACS queue.
- K243341 (Cleared in 2024): The most recent clearance in the AI genealogy, K243341, optimized the software's processing speed, reducing image-analysis time from minutes to seconds, and added support for synthesized 2D images generated by updated versions of C-View.
Clinical Performance and Dense Breast Superiority Labeling
In the competitive breast-imaging market, Hologic's regulatory advantage is sustained by specific, FDA-cleared clinical claims.
1. The Dense Breast Screening Advantage
Approximately 40-50% of women of screening age have dense breast tissue. Dense tissue appears white on a standard mammogram, which can mask cancers (which also appear white). In standard 2D mammography, the sensitivity for dense breasts drops significantly.
- The Labeling Milestone: Hologic's Selenia Dimensions and 3Dimensions systems are marketed as the only mammography systems FDA-approved as superior to standard 2D mammography for women with dense breasts (per Hologic labeling and the Friedewald et al., JAMA 2014 reader study that supported P080003).
- Evidence Base: The PMA approval was supported by multi-site clinical reader studies (notably the Friedewald et al. JAMA 2014 study) showing that adding tomosynthesis to 2D mammography increased detection of invasive cancers while reducing recall rates. Hologic's labeling states the Genius 3D exam detects 20-65% more invasive breast cancers than 2D alone. Competitors such as GE HealthCare (Senographe Pristina) and Siemens Healthineers (Mammomat Inspiration) have also cleared DBT systems, but Hologic's PMA file carries the explicit dense-breast superiority labeling claim.
2. Breast Density Assessment: Quantra Software
To support the screening workflow, Hologic cleared Quantra density assessment software under Class II product code LLZ (System, Image Processing, Radiological). Quantra uses machine-learning models to analyze the volumetric breast density of the patient during the scan, automatically categorizing the patient into one of the four BI-RADS density categories (A, B, C, D). This removes reader subjectivity, ensuring compliance with federal breast density notification laws.
Hologic's Women's Health IVD Footprint: The Panther Platform and Aptima Assays
While Hologic's Breast Health division dominates radiology, its Diagnostics division is a powerhouse in molecular diagnostics, focusing heavily on women's infectious disease screening and cervical cancer prevention.
1. The Panther Molecular Platform
The Panther system is a fully automated, high-throughput molecular diagnostics instrument.
- Regulatory Status: The Panther instrument family is regulated as a 510(k)-exempt Class II device under product code OOI (Instrument for clinical multiplex test systems) and regulation 21 CFR 862.2570. The platform itself therefore does not require a 510(k) clearance; instead, each assay that runs on it carries its own clearance or approval.
- Panther Fusion: Launched in October 2017 as an in-lab module that adds real-time multiplex PCR capability on top of the Panther platform, allowing labs to run both transcription-mediated amplification (TMA) and PCR assays on a single automated system. The first Panther Fusion assay — Flu A/B/RSV — was FDA-cleared alongside the module's commercial launch.
2. Transcription-Mediated Amplification (TMA) vs. Traditional PCR
Hologic's diagnostics portfolio relies heavily on Transcription-Mediated Amplification (TMA), an isothermal nucleic acid amplification method that differs fundamentally from traditional Polymerase Chain Reaction (PCR). While PCR utilizes thermal cycling to amplify DNA targets, TMA amplifies RNA targets (such as ribosomal RNA or messenger RNA) isothermally at a constant temperature ($41.5^\circ\text{C}$). This enables:
- Massive Target Amplification: TMA produces up to 10 billion-fold amplification of RNA targets within an hour.
- Reduced Lab Contamination: Since TMA amplifies RNA rather than DNA, the transcripts are rapidly degraded by ambient RNases, reducing the risk of laboratory amplicon carryover contamination.
- Higher Clinical Sensitivity: The high copy number of rRNA per bacterial cell (often thousands of copies per cell, compared to a single copy of genomic DNA) makes TMA inherently more sensitive for detecting low-titer pathogens.
3. The Aptima Assay Family
Hologic has secured a deep portfolio of PMA approvals, 510(k) clearances, and a de novo authorization for assays running on the Panther platform, forming a comprehensive women's health screening panel:
- Aptima Combo 2 Assay (510(k), Class II): The gold standard for the simultaneous detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). It was the first FDA-cleared molecular diagnostic test for an STI, cleared under 510(k) (product codes MKZ / LSL) rather than PMA, and is widely used in national screening programs.
- Aptima HPV Assay (PMA P100042): Approved for cervical cancer screening, targeting 14 high-risk human papillomavirus types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) via a separate 16/18/45 genotyping assay. The assay is notable because it detects E6/E7 oncogene mRNA rather than viral DNA, and in February 2026 Hologic received FDA approval to expand it to clinician-collected primary screening.
- Aptima BV (510(k) K190452) and Aptima CV/TV (510(k) K190472): Cleared in 2019 (decision date May 23, 2019 for BV) under product code PQA and regulation 21 CFR 866.3975 for the diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (CV), and Trichomonas vaginalis (TV), providing clinicians with a complete vaginitis panel from a single swab.
- Aptima Mycoplasma genitalium (de novo authorization, 2019): The first FDA-authorized test for Mycoplasma genitalium, cleared through the de novo pathway (a low- to moderate-risk new device type) rather than 510(k), establishing the classification and special controls for this STI test type.
Summary of Core Panther Molecular Assays
| Assay Name | Regulatory Pathway | FDA Approval / Clearance | Target Pathogen(s) | Technology Used | Clinical Indication |
|---|---|---|---|---|---|
| Aptima Combo 2 | 510(k) | 510(k) Class II (MKZ / LSL; 21 CFR 866.3390 / 866.390) | Chlamydia trachomatis, Neisseria gonorrhoeae | TMA (Ribosomal RNA target) | First FDA-cleared STI molecular test; dual diagnostic and screening panel. |
| Aptima HPV | PMA | P100042 | 14 High-Risk HPV Genotypes (16, 18, 45, and others) | TMA (E6/E7 oncogene mRNA target) | Cervical cancer screening; mRNA target gives high specificity over viral DNA tests. |
| Aptima Trichomonas vaginalis | 510(k) | 510(k) Class II (cleared 2013) | Trichomonas vaginalis | TMA (Ribosomal RNA target) | First FDA-cleared NAAT for symptomatic or asymptomatic trichomoniasis. |
| Aptima BV | 510(k) | K190452 (05/23/2019) | Gardnerella, Lactobacillus, Atopobium vaginae | TMA (Ribosomal RNA target) | Quantitative ratio detection for Bacterial Vaginosis diagnostics. |
| Aptima CV/TV | 510(k) | K190472 (2019) | Candida species, Trichomonas vaginalis | TMA (Ribosomal RNA target) | Combined diagnostic panel for candidiasis and trichomoniasis. |
| Aptima Mycoplasma genitalium | De Novo | De novo authorization (Jan 2019) | Mycoplasma genitalium | TMA (Ribosomal RNA target) | First FDA-authorized test for M. genitalium in urogenital swabs. |
5. Transitioning to the EU IVDR (2017/746)
Under the EU In Vitro Diagnostic Regulation (IVDR 2017/746) that entered full application in May 2022, Hologic has undergone a major regulatory migration.
- Risk Class Shift: Under the legacy IVD Directive, the majority of Aptima assays were self-certified Class A. Under the IVDR, sex-transmitted infection (STI) assays (like Aptima Chlamydia/Gonorrhoeae) are classified as Class C, and high-risk screening tests (like Aptima HPV) are Class C or Class D (requiring EU Reference Laboratory intervention if clinical risk is critical).
- Notified Body Auditing: Every assay must now undergo a comprehensive performance evaluation (clinical performance, analytical performance, and scientific validity) audited by a Notified Body (such as BSI or TÜV SÜD), requiring a massive administrative transition.
Global Market Access and Registration Strategy
Beyond the United States, Hologic maintains a complex regulatory network to sustain global market access:
1. China NMPA Registration (Class III Hardware)
Securing market access for the 3Dimensions system in China requires navigating the National Medical Products Administration's (NMPA) Class III registration.
- Local Clinical Trial Requirement: Unlike the US FDA's reliance on bench and reader studies, the NMPA historically required local clinical trials involving Chinese patient cohorts to confirm radiological equivalence.
- Type Testing: Systems must undergo local electrical safety type testing (GB 9706.1-2020) at NMPA-certified testing facilities in China before a registration dossier can be submitted, resulting in a registration timeline that typically spans 24-36 months.
2. Japan PMDA Shonin Approvals
In Japan, Hologic's Genius AI CAD software is registered as a Class II medical device, requiring Shonin approval from the PMDA. The PMDA evaluates the algorithm's clinical performance on Japanese breast density profiles (which tend to be denser on average than Western profiles), requiring specialized validation data to ensure accuracy.
3. Streamlining Quality Audits via MDSAP
To support its global commercial operations without duplicating quality system audits, Hologic participates in the Medical Device Single Audit Program (MDSAP). Under MDSAP, a single audit conducted by an authorized Auditing Organisation (AO) satisfies the QMS requirements of five participating regulatory authorities:
- United States: FDA (under 21 CFR 820 / QMSR).
- Canada: Health Canada (under Medical Devices Regulations - SOR/98-282).
- Brazil: ANVISA (under RDC 665/2022).
- Japan: PMDA / MHLW (under Ordinance No. 169).
- Australia: TGA (under Therapeutic Goods Regulations 2002).
Hologic's manufacturing facilities in Marlborough, Massachusetts, and San Diego, California, undergo annual MDSAP audits, which drastically reduces the burden of hosting individual inspectorates from five different countries and accelerates international market clearance pathways.
US Installed Base, Market Penetration, and Reimbursement Coverage
Hologic's regulatory success has translated into near-total market access in the United States.
1. Installed Base Metrics
Hologic has installed more than 5,000 3D Mammography systems in the United States. This represents approximately 60-70% of the active 3D mammography installations in the country. More than 16 million US women receive a Hologic Genius 3D exam each year.
2. Insurance and Reimbursement Coverage
- Medicare Coverage: The Centers for Medicare & Medicaid Services (CMS) established dedicated HCPCS codes for 3D mammography: G0204 (Diagnostic mammography, producing direct digital image, bilateral, all views; includes computer-aided detection) and G0206 (Screening mammography, producing direct digital image, bilateral, all views; includes computer-aided detection). Medicare provides national coverage for screening mammography with zero patient copay under the Affordable Care Act.
- Commercial Payers: The Genius 3D exam is widely covered by commercial payers for screening-age women, driven by the clinical evidence compiled in Hologic's PMA P080003 file and supportive guidelines; Hologic reports the exam is broadly reimbursed across US commercial and Medicare populations.
- State Mandates: The rapid adoption of Hologic's dense breast claim helped drive state-level legislation. Over 40 states now mandate that mammography providers inform patients if they have dense breast tissue, recommending supplemental screening (like 3D tomosynthesis or ultrasound), which has created a continuous tailwind for 3D system upgrades.
Frequently Asked Questions (FAQ)
Was Hologic's Genius 3D Mammography system cleared by 510(k) or approved by PMA?
The hardware platform (Selenia Dimensions 3D / 3Dimensions) was approved by the FDA through the PMA (Premarket Approval) pathway under number P080003 on February 11, 2011. Because it was the first digital breast tomosynthesis system, it was classified as Class III.
What FDA product code applies to Hologic Genius AI Detection software?
Genius AI Detection and Genius AI Detection 2.0 are cleared under product code QDQ (Radiological Computer-Assisted Detection/Diagnosis Software, 21 CFR 892.2090), Class II.
When did the FDA approve the first digital breast tomosynthesis (3D mammography) system?
The FDA approved the first DBT system, Hologic's Selenia Dimensions 3D, on February 11, 2011 under PMA P080003.
What is the difference between Transcription-Mediated Amplification (TMA) and PCR?
TMA is an isothermal RNA amplification method that operates at a constant $41.5^\circ\text{C}$ to amplify RNA targets, whereas PCR is a DNA amplification method requiring temperature cycling. TMA is highly sensitive due to the high copy numbers of target rRNA and is less susceptible to DNA amplicon contamination in molecular labs.
What is the IVDR classification for Hologic's Aptima assays in Europe?
Under the EU IVDR (2017/746), Hologic's STI and high-risk HPV screening assays are classified as Class C medical devices, shifting from legacy self-certification to mandatory Notified Body quality system and performance evaluation audits.
What is the C-View synthesized 2D module and why is it important?
Approved under PMA P080003/S001 in 2013, C-View is a software module that constructs a synthesized 2D mammogram from 3D tomosynthesis data slices. This eliminates the need for a separate 2D X-ray exposure, reducing the radiation dose to the patient by approximately 45%.
How many Hologic 3D Mammography systems are installed in the US?
Hologic has installed more than 5,000 3D Mammography systems in the United States, and more than 16 million women receive a Genius 3D exam annually.
What is MDSAP and how does Hologic use it?
MDSAP is the Medical Device Single Audit Program. It allows Hologic to satisfy the QMS auditing requirements of the US FDA, Health Canada, ANVISA (Brazil), PMDA (Japan), and TGA (Australia) through a single annual quality system audit.
Sources
- US FDA Premarket Approval (PMA) Database:
- Selenia Dimensions 3D System Approval: PMA P080003 Record (February 11, 2011).
- C-View Synthesized 2D Supplement: P080003/S001 SSED (May 16, 2013).
- 3Dimensions System Supplement: P080003/S006 Record (March 23, 2018).
- High Resolution Tomosynthesis: P080003/S008 Record (October 24, 2019).
- Aptima HPV Assay: PMA P100042 Record (E6/E7 mRNA, 14 high-risk HPV types).
- US FDA 510(k) Premarket Notification Database:
- Genius AI Detection First-Gen: K201019 Summary (November 18, 2020; predicate iCAD PowerLook Tomo Detection V2, K182373).
- Genius AI Detection 2.0: K221449 Summary (October 6, 2022).
- Genius AI Detection 2.0 Update: K243341 Summary (2024).
- Affirm Contrast Biopsy: K202294 Summary (Class II, product code IZH, 21 CFR 892.1710).
- Aptima BV Assay: K190452 Record (May 23, 2019; Class II, product code PQA, 21 CFR 866.3975).
- Aptima CV/TV Assay: K190472 Review Memorandum (2019; Class II, product code PQA, 21 CFR 866.3975).
- Quantra 2.2 Breast Density Software: K163623 Summary (Class II, product code LLZ, 21 CFR 892.2050).
- US FDA De Novo & IVD Pathway:
- Aptima Mycoplasma genitalium Assay: FDA de novo authorization (January 2019) — first FDA-authorized M. genitalium test; FDA news release.
- Hologic Corporate & Product Press Materials:
- Genius AI Detection Product Feature: Hologic Product Webpage (2025).
- 3Dimensions system launch & stats: BioSpace Release / Hologic Announce (March 26, 2018).
- Aptima Combo 2 / HPV / Panther timelines: Hologic Product Timeline.
- Hologic Corporate & Product Press Materials:
- Genius AI Detection Product Feature: Hologic Product Webpage (2025).
- 3Dimensions system launch & stats: BioSpace Release / Hologic Announce (March 26, 2018).